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ABSTRACT — The unexpected high revision rates of large-
diameter (femoral head sizes of 36 mm or greater) metal-on-metal 
hip arthroplasties (MoMHAs) have led to worldwide regulatory 
authorities recommending regular surveillance, even for asymp-
tomatic individuals. However, these recommendations are not 
evidence-based and are very costly. The rapidly evolving evidence 
base requires an update regarding the investigation and manage-
ment of MoMHA patients. This article is the fi rst of 2 (the second 
article in this series will consider the threshold for performing 
revision, and the outcomes following ARMD revision surgery: 
Matharu et al., Revision surgery of metal-on-metal hip arthro-
plasties for adverse reactions to metal debris: A clinical update. 
Acta Orthop 2018; in press), and considers the various investi-
gative modalities used during surveillance, with specifi c focus on 
blood metal ion sampling and cross-sectional imaging. No single 
investigation can universally be used during MoMHA patient 
surveillance. Recent studies have now provided important infor-
mation on interpreting blood metal ions (effective in identifying 
patients at low risk of problems), clarifying the roles of cross-sec-
tional imaging (reserve combined ultrasound and MARS-MRI for 
complex cases), and providing parameters to safely exclude many 
asymptomatic patients from regular surveillance. This informa-
tion will be useful when designing future surveillance protocols 
for MoMHA patients
■
Many metal-on-metal hip arthroplasties (MoMHAs) with 
large femoral head diameters (36 mm or greater) have been 
implanted worldwide, either as hip resurfacing arthroplasty 
(HRA) or as total hip arthroplasty (THA) (Bozic et al. 2009, 
NJR 2016). In recent years high short-term failure rates have 
been reported for most large-diameter MoMHA designs, 
which has led to an almost worldwide cessation of their use 
(Smith et al. 2012a, 2012b, AOANJRR 2016, NJR 2016). 
Many MoMHA revisions have been performed for adverse 
reactions to metal debris (ARMD) (Langton et al. 2010, 
2011a) and pseudotumor (a specifi c type of ARMD, defi ned as 
a cystic, solid, or mixed mass communicating with the joint) 
(Pandit et al. 2008). ARMD is the sequela of metal debris 
released from the bearing surface and/or other THA modu-
lar implant junctions due to wear and corrosion (Kwon et al. 
2010, Langton et al. 2011b, Matthies et al. 2011, Langton et 
al. 2012, Jacobs et al. 2014). This debris can result in destruc-
tion of the local bone and soft tissues, as well as large invasive 
pseudotumors, which often require revision surgery (Pandit et 
al. 2008, Grammatopoulos et al. 2009, Langton et al. 2010).
To identify ARMD early, regulatory authorities worldwide 
have published follow-up guidance for MoMHA patients 
(MHRA 2012, FDA 2013, Hannemann et al. 2013). Patients 
with ARMD may be asymptomatic which can make diagnosis 
diffi cult (Hart et al. 2012, Fehring et al. 2014), therefore cur-
rently most MoMHA patients are regularly followed up for 
life. The main investigations used in surveillance are blood 
metal ions and cross-sectional imaging (ultrasound or metal 
artefact reduction sequence magnetic resonance imaging 
(MARS-MRI)) (MHRA 2012, FDA 2013, Hannemann et al. 
2013). However, a recent review of MoMHA follow-up pro-
tocols issued by 5 worldwide authorities demonstrated that 
the guidance was extremely variable between authorities, not 
evidence-based and very costly (Matharu et al. 2015c). Fur-
thermore, there are still a number of questions that need to 
be addressed regarding the specifi c roles of each investigative 
modality during surveillance (Matharu et al. 2015c). 
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This article is the fi rst of 2 providing a clinical update on 
the investigation and management of MoMHA patients. The 
present article considers the various investigative modalities 
used during MoMHA surveillance, with specifi c focus on 
blood metal ion sampling and imaging. The second article 
considers the threshold for performing revision, and the out-
comes following ARMD revision surgery (Acta Orthop 2018; 
in press).
Blood metal ions
Rationale, methods, and interpretation
Blood metal ion concentrations are a surrogate marker of in-
vivo wear in MoMHAs, and therefore have been used to inves-
tigate patients (De Smet et al. 2008). Cobalt and chromium 
ions are measured, which constitute the primary elements of 
the MoM alloy. Wear (normal and excessive) and corrosion 
of MoMHAs causes release of both insoluble metal particles 
(found in the synovial fl uid and periprosthetic tissues) and 
soluble metal ions (entering the bloodstream thus allowing 
measurement) (McMinn 2009).
Whole blood or serum samples are used for measuring these 
metal ion concentrations. Samples should be collected, stored, 
transported, and processed according to laboratory guidance. 
Analysis must be performed at an accredited laboratory with 
expertise in trace metal element analysis, with excellent accu-
racy of measurement and reproducibility reported (Harrington 
and Taylor 2012). Samples are analyzed using dynamic reac-
tion cell or collision cell inductively coupled plasma mass 
spectrometry.
Serial samples should be sent to the same laboratory given 
that clinically signifi cant variations can occur in blood sam-
ples from the same patients analyzed at different laborato-
ries (Rahme et al. 2014). To prevent incorrect interpretation 
of serial results the same blood fraction must be used. Whole 
blood is preferred given that serum requires further prepara-
tion (centrifuging), which increases the risk of contamination 
(Daniel et al. 2007). Serum cobalt and chromium are up to 
1.4 times greater than their respective values in whole blood, 
with stronger correlation of cobalt in serum and whole blood 
compared with that of chromium (Vendittoli et al. 2007, Engh 
et al. 2014).
Advantages of blood metal ion sampling include being 
relatively inexpensive (£30 per test) (Lloyd et al. 2013) and 
simple to conduct. Disadvantages relate to potential patient 
(renal function, diet/medication/supplements containing trace 
metals, occupational exposure, other metal eluting implants) 
and laboratory (contamination, inter-laboratory, and intra-
laboratory measurement variability) factors that can infl uence 
test interpretation (Daniel et al. 2010, FDA 2013, Rahme et 
al. 2014). Therefore, management decisions should never be 
solely based on 1 blood test.
Blood metal ions in healthy controls and well-func-
tioning hips
97% of healthy subjects have both blood cobalt and chromium 
concentrations of 2 µg/L or less, with little variation observed 
between individuals (Sidaginamale et al. 2013). In well-func-
tioning MoMHAs, metal ions can enter the bloodstream by day 
5 following implantation (Daniel et al. 2007). Blood metal ion 
concentrations then increase signifi cantly over the fi rst year 
during the bearing running-in phase (Heisel et al. 2008). Con-
centrations then either stabilize or slowly decrease from 1 year 
postoperatively during medium-term follow-up (Daniel et al. 
2007, 2009, Amstutz et al. 2013). However, some authors have 
also observed signifi cantly decreased blood metal ion concen-
trations by 10 years (Bernstein et al. 2012, Van Der Straeten 
et al. 2013a, 2013b).
Factors infl uencing blood metal ion concentrations
High blood metal ion concentrations in MoMHA patients 
have been associated with poorly functioning implants (Hart 
et al. 2011a, Van Der Straeten et al. 2013a, Hart et al. 2014), 
including those specifi cally revised for ARMD (Langton et al. 
2010, Sidaginamale et al. 2013, Lainiala et al. 2014b, Lang-
ton et al. 2016). Predictors of raised blood metal ion concen-
trations can be divided into patient (female sex, young age, 
time since implantation), implant (design, small femoral HRA 
components, large femoral MoM THA components, bilateral 
MoMHAs), and surgical factors (acetabular component mal-
position, reduced contact patch to rim distance) (De Haan et 
al. 2008, Langton et al. 2009, Grammatopoulos et al. 2010a, 
Bernstein et al. 2011, Hart et al. 2011b, Langton et al. 2011c, 
Lavigne et al. 2011, Chang et al. 2013, Van Der Straeten et al. 
2013a, Emmanuel et al. 2014, Matthies et al. 2014, Matharu et 
al. 2015a, 2015b, Lainiala et al. 2016).
A recent large study involving 1,748 patients with differ-
ent MoMHA implant designs observed that MoM THAs had 
signifi cantly higher blood metal ion concentrations compared 
with HRA patients (Lainiala et al. 2016). This confi rms the 
fi ndings from 2 randomized controlled trials of MoM THAs 
and HRAs with identical bearing surfaces (Garbuz et al. 2010, 
Beaule et al. 2011), with the higher metal ion concentrations 
in MoM THAs likely to be related to the additional wear and 
corrosion occurring at the modular implant junction(s).
Blood metal ion thresholds for clinical use
There is presently no international consensus on the accept-
able metal ion threshold(s) of concern in MoMHA patients. 
Since 2010, blood cobalt and/or chromium concentrations 
above 7 µg/L have been considered a cause for concern by 
some authorities (MHRA 2010, Canada 2012, MHRA 2012, 
2015). Initial reports suggested that this arbitrarily selected 
threshold had good specifi city (89%) but poor sensitiv-
ity (52%) for detecting unilateral failed MoMHAs, with the 
optimal threshold identifi ed as a cobalt or chromium of 5.0 
µg/L (86% specifi city and 63% sensitivity) (Hart et al. 2011a). 
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Others have reported similar fi ndings (Malek et al. 2012). A 
subsequent study involving 597 unilateral MoMHAs identi-
fi ed 7 µg/L as having nearly optimal misclassifi cation rates, 
although the authors suggested blood metal ions should not be 
used alone for screening for failed implants (Hart et al. 2014).
Thresholds for poorly functioning HRAs have been pro-
posed by Van Der Straeten et al. (2013a) (cobalt 4.0 µg/L and 
chromium 4.6 µg/L for unilateral HRA) and others (cobalt 4.5 
µg/L) (Sidaginamale et al. 2013) with all cut-offs having higher 
specifi city than sensitivity. Similar fi ndings were observed in 
poorly functioning bilateral HRAs (Van Der Straeten et al. 
2013a). Blood metal ion concentrations above 20 µg/L have 
been associated with osteolysis at ARMD revision, there-
fore it was recommended that revision should be considered 
in patients above this threshold (Langton et al. 2013). More 
recently a US consensus statement proposed risk-stratifying 
MoMHA patients to assist management with blood cobalt and 
chromium concentrations arbitrarily grouped into low risk (< 
3 µg/L), moderate risk (3–10 µg/L), and high risk (> 10 µg/L) 
(Kwon et al. 2014).
2 large cohort studies involving 783 MoMHA patients 
recently devised implant-specifi c blood metal ion thresholds 
for unilateral Birmingham Hip Resurfacings (BHRs, Smith 
& Nephew, Warwick, UK: cobalt 2.15 µg/L), bilateral BHRs 
(maximum cobalt or chromium 5.5 µg/L), and unilateral 
Corail-Pinnacle THAs (DePuy, Leeds, UK: cobalt 3.57 µg/L) 
(Matharu et al. 2016a, 2016b). Patients with ion concentra-
tions below the respective newly devised thresholds were at 
a low risk of having ARMD. However, these new thresholds 
were not effective for identifying patients who had ARMD. 
Currently proposed fi xed regulatory authority thresholds from 
the UK MHRA and US surgeons missed more patients with 
ARMD compared with the newly devised thresholds (MHRA 
2012, Kwon et al. 2014). The fi ndings from these 2 studies 
were successfully validated in 710 patients from 3 different 
European centers (Matharu et al. 2017a). It was therefore 
recommended that the newly devised implant-specifi c blood 
metal ion thresholds should be used in preference to fi xed 
regulatory authority thresholds when managing MoMHA 
patients.
Repeat blood metal ion sampling
After repeating blood metal ions within 1 year in 254 unilat-
eral Articular Surface Replacement (ASR, DePuy) patients, 1 
study observed that most HRAs had concentrations below pub-
lished thresholds (Van Der Straeten et al. 2013a) on both tests, 
whilst one-third of MoM THAs with normal initial cobalt con-
centrations experienced signifi cant increases on repeat testing 
(Reito et al. 2014b). Similar observations were reported in 
bilateral ASR patients undergoing repeat blood testing (Reito 
et al. 2016). Another study repeating blood metal ions during 
the short term in 205 patients with HRAs observed that cobalt 
concentrations did not signifi cantly change with time since 
implantation (Langton et al. 2013). 
Hip imaging
Radiographs
Conventional radiographs provide important information on 
component position, bone quality, and implant fi xation, there-
fore they can identify signs suggestive of MoMHA failure 
early (Chen et al. 2011). However radiographs cannot directly 
diagnose ARMD or pseudotumors, given that these are pre-
dominantly soft-tissue lesions (Johnston et al. 2007, Toms et 
al. 2008), but they can identify associated abnormalities includ-
ing component loosening, osteolysis, femoral neck narrowing, 
component malposition, fracture, subluxation/dislocation, and 
in HRAs femoral neck erosion due to impingement (Gramma-
topoulos et al. 2010a, 2010b, Chen et al. 2011, De Smet et al. 
2011, Langton et al. 2011b, Kwon et al. 2014, Matharu et al. 
2014). Furthermore, radiographs can identify other causes of hip 
pain, such as heterotopic ossifi cation (HO) (Chen et al. 2011).
When assessing radiographs, it is important to compare 
serial images, including the immediate post-primary radio-
graph, for subtle signs of MoMHA failure. Medial calcar ero-
sion represents a radiographic sign suggestive of ARMD in 
MoM THAs (Madanat et al. 2016). A recent case-control study 
involving 384 HRAs demonstrated that radiographic factors 
predictive of hips with evidence of a pseudotumor included 
acetabular component malposition (high inclination, and ante-
version below 5 degrees), acetabular osteolysis, femoral oste-
olysis, acetabular loosening, and the absence of HO (Matharu 
et al. 2017b). However, it was recommended that radiographs 
should not be considered a substitute for performing blood 
metal ions and cross-sectional imaging, given that 20% of 
HRAs revised for pseudotumors had normal radiographs 
(Matharu et al. 2017b). It remains unclear whether femoral 
neck narrowing represents a normal physiological process fol-
lowing HRA or a clinically signifi cant fi nding given that neck 
narrowing has been reported in both well-functioning patients 
(Hing et al. 2007, Coulter et al. 2012, Daniel et al. 2014) and 
ARMD revisions (Chen et al. 2011, Matharu et al. 2014).
Advantages of conventional radiographs when assessing 
MoMHAs include their wide availability, low cost, and ease of 
interpretation, with the main disadvantage being pelvic radia-
tion exposure.
Ultrasound
Ultrasound has frequently been used as the initial imag-
ing modality for investigating MoMHA patients (Fang et al. 
2008, Douis et al. 2012, Nishii et al. 2012). Compared with 
MARS-MRI, the main advantages of ultrasound include being 
cheaper (ultrasound £49 vs. MARS-MRI £216) (Lloyd et al. 
2013), faster to perform, not being affected by prosthetic arte-
facts, and being more accessible with fewer patient contraindi-
cations (can be used in patients with pacemakers or those with 
claustrophobia) (Siddiqui et al. 2014). Ultrasound also per-
mits dynamic imaging, hip aspirations, and biopsies (Kwon 
et al. 2011, Siddiqui et al. 2014). The main disadvantages of 
ultrasound include the technique being operator dependent, 
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and diffi culties when assessing deeper structures or examin-
ing larger patients (Kwon et al. 2014, Siddiqui et al. 2014).
Ultrasound can identify numerous abnormalities around 
MoMHAs (Nishii et al. 2012), including pseudotumors of vari-
able sizes, which are often cystic or solid and located anterior 
or posterolateral to MoMHAs (Figure) (Fang et al. 2008, Kwon 
et al. 2011, Williams et al. 2011, Nishii et al. 2012). A recent 
study of 82 MoMHAs undergoing revision concluded that 
ultrasound was effective for intraoperative detection of pseudo-
tumors (Lainiala et al. 2015). Ultrasound has also been useful 
for detecting other ARMD pathology including joint effusions, 
iliopsoas and trochanteric bursal collections, capsular and 
bursal thickening, and synovitis (Douis et al. 2012, Nishii et al. 
2012). Other abnormalities that ultrasound can identify, which 
may not always be related to ARMD, include muscle atrophy 
and tendon avulsions (Sofka et al. 2004, Garcia et al. 2010).
3 systems for classifying ARMD abnormalities on ultra-
sound have been proposed (Nishii et al. 2012, Siddiqui et al. 
2013, Matharu et al. 2016c). It must be acknowledged that 
the prevalence of ARMD in MoMHAs on both ultrasound and 
MARS-MRI has been much higher (up to 61%) (Kwon et al. 
2011, Williams et al. 2011, Hart et al. 2012, Fehring et al. 
2014) than that confi rmed at revision surgery (Langton et al. 
2016, Matharu et al. 2016d, 2017c). As ARMD on imaging 
has now frequently been observed around well-functioning 
conventional THAs (Bisseling et al. 2015, van der Veen et al. 
2015, Das et al. 2016), it is possible that current cross-sec-
tional imaging classifi cations have over-diagnosed imaging 
ARMD in MoMHA patients (Anderson et al. 2011, Hart et al. 
2012, Hauptfl eisch et al. 2012, Nishii et al. 2012, Siddiqui et 
al. 2013, Matharu et al. 2016c).
Ultrasound has a role in identifying both the development 
and progression of ARMD. Repeat ultrasound in a small 
MoMHA cohort with asymptomatic ARMD on initial imaging 
demonstrated that most lesions increased in size in the short 
term with occasional remission of small masses (Almousa et 
al. 2013). By contrast, a recent study repeated ultrasounds in 
10 HRAs with asymptomatic pseudotumors between 4.0 and 
6.5 years later, with no changes occurring in pseudotumor 
volume or patient reported outcomes (Matharu et al. 2016f). 
This may suggest that some asymptomatic ARMD lesions can 
be safely left and only monitored with interval scanning.
A recent prospective longitudinal study of 152 asymptom-
atic HRAs demonstrated that 10% developed new pseudotu-
mors on ultrasound within 5 years of initial assessment (Low 
et al. 2016). No asymptomatic patients with both a normal 
initial ultrasound and low blood metal ions (< 2 µg/L) devel-
oped new pseudotumors within 5 years of initial assessment 
(33% of hips studied). It was therefore concluded that these 
particular patients do not need regular follow-up. As large 
cohort studies have reported that 84% of all comprehensively 
investigated HRA patients were asymptomatic with well-
functioning devices (Hart et al. 2014), it is estimated that 
28% of all hip resurfacing patients would be asymptomatic 
with normal cross-sectional imaging and low blood metal 
ions. These fi ndings have important clinical and fi nancial 
implications, given that several protocols recommend inten-
sive surveillance for asymptomatic HRA patients (Thera-
peutic Goods Administration 2012, Hannemann et al. 2013, 
MHRA 2015). By contrast asymptomatic HRA patients with 
normal initial ultrasounds alone but ions of 2 µg/L or above, 
and those asymptomatic HRA patients with low blood metal 
ions but abnormal imaging both still had a small, but poten-
tially clinically signifi cant, risk of developing new pseudotu-
mors within 5 years of initial assessment (Low et al. 2016). 
Therefore it was recommended that this patient subgroup 
required some form of surveillance within 5 years of initial 
assessment.
MARS-MRI
Most centers use MARS-MRI as the initial cross-sectional 
imaging modality for investigating MoMHAs, which is likely 
to be increasingly used as techniques become refi ned (Kwon 
et al. 2014). MARS-MRI is not operator dependent, it pro-
vides excellent visualization of soft-tissue structures includ-
ing deeper tissues, and images can be assessed retrospectively, 
which is helpful when obtaining further opinions or planning 
revision (Liddle et al. 2013, Siddiqui et al. 2014). Comparison 
can be made with the contralateral hip, and it is also easier 
to compare serial MARS-MRI images rather than serial 
ultrasounds (Siddiqui et al. 2014). The main disadvantages 
of MARS-MRI include the high cost (£216), periprosthetic 
metal artefact despite suppression techniques, longer exami-
nation times, reduced availability, and being contraindicated 
in patients with pacemakers (Siddiqui et al. 2014).
Pseudotumor in association with a metal-on-metal hip resurfacing 
arthroplasty identifi ed on ultrasound examination. Anterior view of the 
hip demonstrating an enlarged mixed pseudotumor lying in the psoas 
bursa region. The pseudotumor lies in close proximity to the femoral 
vessels (marked) and has a smaller medial (M) and a larger lateral (L) 
component.
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When pseudotumors have been detected, MARS-MRI 
can provide detailed information regarding any soft-tissue 
or muscle invasion and destruction as well as neurovascular 
involvement, which assists when planning revision (Liddle et 
al. 2013). Furthermore, studies by Liddle et al. (2013) (85% 
sensitivity and 59% specifi city) and Lainiala et al. (2014a) 
(71% sensitivity and 87% specifi city) have demonstrated that 
MARS-MRI is effective for diagnosing intraoperative pseudo-
tumors. The latter study also reported that these results varied 
with MARS-MRI timing, with scans performed more than 1 
year before revision surgery having lower sensitivity (29%) 
for detecting intraoperative pseudotumors compared with 
scans performed within 1 year before revision (77–88% sensi-
tivity) (Lainiala et al. 2014a).
Other ARMD abnormalities also detected on MARS-MRI 
include muscle atrophy, tendon avulsions, and osteolysis 
(Hayter et al. 2012, Siddiqui et al. 2014, Berber et al. 2015b, 
Matharu et al. 2016c). Hip abductor atrophy has frequently 
been reported in MoMHAs and can progress over 1 year, with 
some suggesting atrophy may be a precursor to irreversible 
muscle destruction (Berber et al. 2015b).
Like ultrasound, MARS-MRI can identify both the develop-
ment and progression of ARMD associated with MoMHAs. 
Most studies repeating MARS-MRI in MoMHA patients with 
normal initial scans have observed that few changes occur 
within 2 years of repeat imaging (van der Weegen et al. 2013, 
Reito et al. 2014a), with any development of ARMD from 
normal scans occurring over several years (Ebreo et al. 2013). 
By contrast, a study of 155 MoM THAs undergoing repeat 
MARS-MRI within a mean time of 15 months after the ini-
tial imaging observed that the risk of disease progression was 
high in patients with initially normal scans (30%), and in those 
with isolated trochanteric fl uid (47%) and effusions (58%) on 
initial MARS-MRI (Briant-Evans et al. 2015). Disease pro-
gression on imaging was associated with high blood cobalt 
concentrations, or an irregular pseudocapsule lining at initial 
MARS-MRI (Briant-Evans et al. 2015).
Of the 4 studies repeating MARS-MRI in MoMHA patients 
with asymptomatic pseudotumors, 3 reported either little 
change or partial regression with serial imaging (van der 
Weegen et al. 2013, Kwon et al. 2016b, Goldstein et al. 2016). 
The other, a small study of 24 hips, observed that pseudo-
tumors frequently changed in size when MARS-MRI was 
repeated, with larger lesions most likely to increase (Hasegawa 
et al. 2014).
Ultrasound vs. MARS-MRI
A number of studies have compared ultrasound and MARS-
MRI for detecting ARMD (Table) (Garbuz et al. 2014, Nishii 
et al. 2014, Siddiqui et al. 2014, Muraoka et al. 2015, Kwon 
et al. 2016a, Matharu et al. 2016e). The benchmark for diag-
nostic accuracy in such studies should be correlation with the 
fi ndings at revision; however, most did not use intraopera-
tive fi ndings as the reference standard. Studies have largely 
demonstrated that ultrasound was effective for identifying 
pseudotumors on MARS-MRI, and therefore recommended 
ultrasound for initial screening, with MARS-MRI reserved if 
ultrasound abnormalities required further assessment (Garbuz 
et al. 2014, Nishii et al. 2014, Muraoka et al. 2015, Kwon et al. 
2016a). 1 study concluded that a negative ultrasound excluded 
pseudotumor in asymptomatic patients; ultrasound was 100% 
sensitive (Garbuz et al. 2014). Furthermore another study 
Summary of studies comparing ultrasound and MARS-MRI for detecting adverse 
reactions to metal debris and pseudotumors
   Positive Negative
 Sensitivity Specifi city predictive predictive
Study (participants)  (%)  (%) value (%) value (%)
Garbuz et al. 2014 (40 hips)
 Ultrasound vs. MARS-MRI a 100 96 92 100
 MARS-MRI vs. ultrasound a 92 100 100 96
Siddiqui et al. 2014 (19 hips)
 Ultrasound vs. MARS-MRI a 69 83 90 56
Nishii et al. 2014 (64 hips)
 Ultrasound vs. MARS-MRI a 74 92 NS NS
Muraoka et al. 2015 (83 hips)
 Ultrasound vs. MARS-MRI a 72 88 65 91
Kwon et al. 2016a (42 hips)
 Initial: Ultrasound vs. MARS-MRI a 81 92 86 88
 Repeat: Ultrasound vs. MARS-MRI a 86 88 75 94
Matharu et al. 2016e (40 hips)
 Ultrasound vs. intraoperative a 91 43 88 50
 MARS-MRI vs. intraoperative a 94 57 91 67
 Combined imaging (ultrasound & 
 MARS-MRI) vs. intraoperative a 100 57 92 100
NS = not stated. 
a Gold reference standard for diagnostic test characteristics
  Using an optimized MARS-MRI protocol 
allows detection of numerous abnormalities 
around MoMHAs. Pseudotumors are fre-
quently of variable sizes, located anterior or 
posterolateral to MoMHAs, with a cystic, 
solid, or mixed consistency (Wynn-Jones et 
al. 2011, Hart et al. 2012, Hauptfl eisch et al. 
2012, Fehring et al. 2014). 3 main MARS-
MRI pseudotumor classifi cation systems have 
been proposed (Anderson et al. 2011, Hart et 
al. 2012, Hauptfl eisch et al. 2012). Compari-
son of these systems suggested the Ander-
son et al. classifi cation was most reliable 
(van der Weegen et al. 2014). The Modifi ed 
Oxford Classifi cation has been proposed more 
recently (Briant-Evans et al. 2015), which 
classifi es MARS-MRI scans initially into 4 
groups (normal, trochanteric fl uid, effusion, 
ARMD), with the ARMD group subsequently 
classifi ed according to others (Hauptfl eisch et 
al. 2012). However small periprosthetic effu-
sions may still be missed because of prosthetic 
artefacts (Siddiqui et al. 2014).
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repeated both the ultrasound and MARS-MRI in 42 MoMHAs 
after a mean time of 14 months; when ultrasound was repeated 
it was accurately able to detect changes in ARMD lesion size 
and grade, therefore suggesting ultrasound is effective in the 
longitudinal assessment of MoMHA patients (Kwon et al. 
2016a). By contrast, the authors of the smallest study reported 
that ultrasound was inferior to MARS-MRI for detecting pseu-
dotumors and muscle atrophy, but ultrasound was superior to 
MARS-MRI for diagnosing effusions and tendon pathology 
(Siddiqui et al. 2014).
A recent retrospective diagnostic accuracy study of 40 HRAs 
subsequently requiring revision surgery for any reason com-
pared the imaging fi ndings prior to revision with the intraop-
erative fi ndings (Matharu et al. 2016e). It was concluded that 
ultrasound and MARS-MRI both have a role when assessing 
HRA patients requiring revision, which parallels other studies 
where either ultrasound or MARS-MRI alone was performed 
(Liddle et al. 2013, Lainiala et al. 2014a, 2015). However, 
combined imaging using ultrasound and MARS-MRI was 
most effective for both identifying and excluding intraopera-
tive pseudotumors (Table 1). These observations suggest that 
combined imaging may be useful in more complex clinical 
cases, such as symptomatic patients with either a normal ini-
tial ultrasound or MARS-MRI.
Computed tomography
Computed tomography (CT) scanning provides useful 
information regarding MoMHA component positioning and 
fi xation, and can also detect osteolysis or fractures, which 
may be radiographically occult (Hart et al. 2009, Roth et 
al. 2012, Liddle et al. 2013). However, CT appears unsuit-
able for routine MoMHA imaging with a sensitivity of 44% 
for diagnosing pseudotumors compared with MARS-MRI, 
although CT was superior for detecting osteolysis (Robin-
son et al. 2014).
Given the advantages of both ultrasound and MARS-MRI, 
CT should not be recommended as a fi rst-line MoMHA imag-
ing modality (FDA 2013, Hannemann et al. 2013). Further-
more, CT is associated with pelvic radiation, image artefact 
from prostheses, and high costs.
Other investigations
Infection and ARMD can have similar presentations, therefore 
a comprehensive assessment is required. This includes blood 
tests for the erythrocyte sedimentation rate (ESR) and C-reac-
tive protein (CRP). Infected MoMHA revision patients have 
signifi cantly higher ESR and CRP values compared with non-
infected revision cases (which included ARMD failures) (Yi 
et al. 2015). However, the ESR and CRP may also be raised 
in aseptic ARMD patients (Pandit et al. 2008, Mikhael et al. 
2009), and where ARMD and infection coexist (Watters et al. 
2010, Judd and Noiseux 2011, Matharu et al. 2014).
Hip aspirations can help assess infection (synovial fl uid 
culture, sensitivity, white blood cell count, and cell differen-
tial, i.e. percentage of polymorphonuclear cells) (Lombardi 
et al. 2012, Yi et al. 2015) and ARMD (synovial cobalt and 
chromium concentrations) (De Smet et al. 2008, Langton 
et al. 2010, Davda et al. 2011, Kwon et al. 2011). Synovial 
metal ion concentrations can assist in cases where blood metal 
ions and cross-sectional imaging have been equivocal despite 
clinical concerns, and may be informative when patients have 
problematic bilateral MoMHAs. In a recent study leukocyte 
esterase strip testing of synovial fl uid samples was reliable at 
ruling out infection in MoMHAs revised for ARMD (Tischler 
et al. 2016).
Other useful investigations for unexplained symptoms 
include single-photon emission CT (Berber et al. 2015a), 
diagnostic hip injections, and investigating other causes (such 
as spinal or non-orthopedic pathology).
Symptoms and patient-reported outcome 
measures
When interpreting the results of any investigations performed 
in MoMHA patients, pain and functional limitations should 
be assessed. Symptoms and signs looked for are pain (groin, 
buttock, lateral hip, or thigh), swellings or masses, mechani-
cal symptoms (clicking, clunking, grinding, squeaking, catch-
ing, or instability), or a limp when walking. Patient-reported 
outcome measures such as the Oxford Hip Score (OHS) and 
Harris Hip Score (HHS) are reliable and responsive instru-
ments; however, regulatory authorities do not currently 
provide guidance on meaningful thresholds for stratifying 
MoMHA patients (Matharu et al. 2015c). 
An OHS less than 34, or an HHS less than 80 (Kalairajah 
et al. 2005, Murray et al. 2007) could be considered subop-
timal patient-reported outcome measures following MoMHA 
that warrant further investigation. Indeed, a recent large cohort 
study which developed a clinical scoring system for assess-
ing the risk of revision in 1,434 MoMHAs identifi ed the HHS 
and blood metal ion levels as the most important predictors 
of revision. The HHS was subsequently categorized into low 
risk (80–100), moderate risk (70–79), and high risk (< 70) 
groups (Hussey et al. 2016). Patient-reported outcome mea-
sures therefore seem important for risk stratifying MoMHA 
patients who otherwise may not appear to be symptomatic for 
surveillance and/or further investigation.
Conclusions
Many studies have assessed various investigative modalities 
used in MoMHA surveillance. No single investigation can 
universally be used during surveillance based on our literature 
update. We recommend that all MoMHA patients undergo a 
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complete clinical assessment as a baseline. This assessment 
should include blood metal ion concentrations, cross-sectional 
imaging, and pelvic radiographs as well as completion of 
validated patient-reported outcome measures. The choice of 
cross-sectional imaging modality (ultrasound or MARS-MRI) 
used will depend on the availability of ultrasound expertise 
at each institution as well as any fi nancial constraints. Sub-
sequent patient management will depend on a combination 
of the results of this clinical assessment, hip symptoms, and 
the patient’s risk of ARMD (Grammatopoulos et al. 2010a, 
Matharu et al. 2016d).
Recent studies have provided information about (1) inter-
preting blood metal ions (effective at identifying patients at 
low risk of ARMD), (2) the roles of cross-sectional imaging 
(reserve combined ultrasound and MARS-MRI for complex 
cases), and (3) providing evidence-based parameters (blood 
metal ions < 2 µg/L and normal cross-sectional imaging) to 
safely exclude many asymptomatic patients from regular sur-
veillance. The latter issue is particularly important in asymp-
tomatic HRA patients and could result in considerable fi nan-
cial savings, given that the current recommendations from 
regulatory authorities for this subgroup vary ranging from 
local protocol (MHRA 2012) to annual radiographs and blood 
metal ions (Hannemann et al. 2013). Therefore, the fi ndings 
from recent studies will be useful when designing future sur-
veillance protocols for MoMHA patients. However, the natu-
ral history of ARMD remains incompletely understood. Fur-
ther longitudinal studies are thus needed to identify specifi -
cally which clinical, laboratory, and imaging fi ndings predict 
patients with aggressive ARMD requiring revision surgery.
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